4DMedical Stock And 2 Other Australian Growth Stocks To Own

Bond markets are now lifting borrowing costs on their own, as rising yields tighten conditions for governments and businesses. Higher rates can make life harder for weaker companies, yet they also sharpen the focus on Australian businesses that analysts expect to grow earnings while keeping balance sheets in reasonable shape. This article walks through three such growth candidates from our screener and explains what makes each one worth a closer look.

The three stocks in focus below are only a sample from this theme, since the full screen surfaced 91 more businesses with similarly compelling growth stories and financial profiles that are not covered in this article. To see the wider opportunity set, head straight into the Healthy high growth potential screener to identify, analyze and prioritise the healthiest high growth candidates for your watchlist.

4DMedical (ASX:4DX)

4DMedical is a lung imaging specialist that fits this healthy high growth potential theme through its non invasive respiratory software suite used in screening, diagnostics and drug development, generating about A$7 million from lung function analysis and carrying a market value of roughly A$2.4b.

For investors hunting for earnings acceleration tied directly to real-world healthcare adoption, 4DMedical offers a pure play on quantitative lung imaging that plugs into screening programs, hospital workflows and pharmaceutical trials in a way few listed peers can match.

"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America."

What happens to 4DMedical’s growth story if a single assumption about how quickly clinicians change long-established scanning habits proves too optimistic?

If that adoption curve is what you are testing, the full narrative for 4DMedical describes how clinician behaviour, Philips volumes and funding cycles could accelerate or stall the 4DMedical thesis.

Catalyst Metals (ASX:CYL)

Catalyst Metals is a Perth based gold producer and explorer, with the Plutonic Gold Belt mines in Western Australia contributing to its “healthy high growth potential” profile through ongoing exploration and development. It generated about A$629 million from Western Australia operations and has a market value near A$1.5b.

Catalyst Metals aligns with this screen, with analysts expecting earnings to grow 23.18% a year as Plutonic Main and Plutonic East contribute to A$631.94 million in sales and 27.1% net margins. The main question is how those margins might be affected if one of the pressures on future project economics changes.

If you want to see how those pressures and opportunities stack up for Catalyst Metals, go straight to the 5 key rewards and 1 important major warning sign for the full picture hiding underneath.

Netwealth Group (ASX:NWL)

Netwealth Group runs a wealth management platform that fits this healthy high growth potential screen through its fee-based super and investment services, with A$389.7 million from platform operations in Australia and a market value around A$4.3b.

Netwealth Group matters for this theme because its wealth platform already generates recurring fees from adviser and client money, and recent product moves could widen that pool if they land as intended.

"Netwealth's continued investment in best-in-class digital experience, platform functionality, and data analytics aligns with the ongoing digitisation of financial services and increasing regulatory focus on transparency. This positions the company to capture greater adviser and client net inflows, bolster revenue growth, and strengthen platform stickiness."

The real swing factor is whether one subtle shift in how advisers route high value client assets ends up reshaping future fee margins.

If that shift in adviser flows is what you are weighing up, the full narrative for Netwealth Group explains how Netwealth Group could see fees accelerate or stall from here.

Seeking Alternatives Before Momentum Flies

Fresh ideas tend to move first. Once momentum hits, entry points shrink, prices gap on breakouts, and trailing buyers get caught chasing. Scan these under the radar lists and consider acting early.

• Identify resilient compounders before defensive money chases them by filtering for strong balance sheets and sturdy fundamentals with the curated list of solid balance sheet and fundamentals (12 results).
• Track potential income opportunities while yields remain elevated by reviewing high payout candidates inside the hand picked 6 dividend fortresses.
• Review grid modernisation players positioned for potential infrastructure funding activity in the focused 43 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com